215 related articles for article (PubMed ID: 37647867)
1. Modulation of AMPK Significantly Alters Uveal Melanoma Tumor Cell Viability.
Deliktas O; Gedik ME; Koc I; Gunaydin G; Kiratli H
Ophthalmic Res; 2023; 66(1):1230-1244. PubMed ID: 37647867
[TBL] [Abstract][Full Text] [Related]
2. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial DNA polymorphisms and biogenesis genes in primary and metastatic uveal melanoma cell lines.
Singh L; Atilano SR; Jager MJ; Kenney MC
Cancer Genet; 2021 Aug; 256-257():91-99. PubMed ID: 34082186
[TBL] [Abstract][Full Text] [Related]
4. Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes.
Sundaramurthi H; Tonelotto V; Wynne K; O'Connell F; O'Reilly E; Costa-Garcia M; Kovácsházi C; Kittel A; Marcone S; Blanco A; Pallinger E; Hambalkó S; Piulats Rodriguez JM; Ferdinandy P; O'Sullivan J; Matallanas D; Jensen LD; Giricz Z; Kennedy BN
Open Res Eur; 2023; 3():88. PubMed ID: 37981907
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells.
Yan F; Liao R; Farhan M; Wang T; Chen J; Wang Z; Little PJ; Zheng W
Biomed Pharmacother; 2016 Dec; 84():1538-1550. PubMed ID: 27881235
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
8. Anticancer effects of mifepristone on human uveal melanoma cells.
Alvarez PB; Laskaris A; Goyeneche AA; Chen Y; Telleria CM; Burnier JV
Cancer Cell Int; 2021 Nov; 21(1):607. PubMed ID: 34789240
[TBL] [Abstract][Full Text] [Related]
9. Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway.
Kaushik G; Kwatra D; Subramaniam D; Jensen RA; Anant S; Mammen JM
Am J Surg; 2014 Dec; 208(6):995-1002; discussion 1001-2. PubMed ID: 25450590
[TBL] [Abstract][Full Text] [Related]
10. Pristimerin effectively inhibits the malignant phenotypes of uveal melanoma cells by targeting NF‑κB pathway.
Zhang B; Zhang J; Pan J
Int J Oncol; 2017 Sep; 51(3):887-898. PubMed ID: 28766683
[TBL] [Abstract][Full Text] [Related]
11. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract][Full Text] [Related]
12. PARK7/DJ-1 inhibition decreases invasion and proliferation of uveal melanoma cells.
Lago-Baameiro N; Santiago-Varela M; Camino T; Silva-Rodríguez P; Bande M; Blanco-Teijeiro MJ; Pardo M; Piñeiro A
Tumori; 2023 Feb; 109(1):47-53. PubMed ID: 34918581
[TBL] [Abstract][Full Text] [Related]
13. Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.
Weidmann C; Bérubé J; Piquet L; de la Fouchardière A; Landreville S
Clin Exp Metastasis; 2018 Mar; 35(3):123-134. PubMed ID: 29696577
[TBL] [Abstract][Full Text] [Related]
14. RNA m
Luo G; Xu W; Zhao Y; Jin S; Wang S; Liu Q; Chen X; Wang J; Dong F; Hu DN; Reinach PS; Yan D
J Cell Physiol; 2020 Oct; 235(10):7107-7119. PubMed ID: 32017066
[TBL] [Abstract][Full Text] [Related]
15. Uveal melanoma cell lines Mel270 and 92.1 exhibit a mesenchymal phenotype and sensitivity to the cytostatic effects of transforming growth factor beta in vitro.
Doudnikoff C; Leclerc D; Angenard G; Gilot D; Coulouarn C; Mouriaux F
Mol Vis; 2024; 30():160-166. PubMed ID: 38601020
[TBL] [Abstract][Full Text] [Related]
16. Electrochemotherapy with bleomycin and cisplatin enhances cytotoxicity in primary and metastatic uveal melanoma cell lines in vitro.
Fiorentzis M; Kalirai H; Katopodis P; Seitz B; Viestenz A; Coupland SE
Neoplasma; 2018; 65(2):210-215. PubMed ID: 29534581
[TBL] [Abstract][Full Text] [Related]
17. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.
Yang JY; Li Y; Wang Q; Zhou WJ; Yan YN; Wei WB
Chin Med J (Engl); 2020 Aug; 133(16):1922-1929. PubMed ID: 32826455
[TBL] [Abstract][Full Text] [Related]
19. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
Shu W; Zhu X; Wang K; Cherepanoff S; Conway RM; Madigan MC; Zhu H; Zhu L; Murray M; Zhou F
Cell Oncol (Dordr); 2022 Aug; 45(4):601-619. PubMed ID: 35781872
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of microRNA-130a represses uveal melanoma cell migration and invasion through inactivation of the Wnt/β-catenin signaling pathway by downregulating USP6.
Wu S; Han M; Zhang C
Cancer Gene Ther; 2022 Jul; 29(7):930-939. PubMed ID: 34522027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
